MedTrace Logo

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

NCT02576327 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2016-12-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Conditions

Interventions

DRUG

Tropisetron

Tropisetron Hydrochloride Injection 5mg (Day 1-6)

DRUG

Dexamethasone

Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)

DRUG

Aprepitant

Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)

Sponsors & Collaborators

  • Jun Zhu

    lead OTHER

Principal Investigators

  • Jun Zhu, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-10-31
Completion
2017-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02576327 on ClinicalTrials.gov